{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T09:23:29Z","timestamp":1790241809607,"version":"4.1.0"},"reference-count":119,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 CA258886-01"],"award-info":[{"award-number":["R01 CA258886-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017556","name":"Marie-Jos\u00e9e and Henry R. Kravis Center for Molecular Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017556","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017050","name":"Cycle for Survival","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"US Department of Defense","doi-asserted-by":"publisher","award":["KC180165"],"award-info":[{"award-number":["KC180165"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Cell"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ccell.2026.05.007","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T14:41:12Z","timestamp":1780584072000},"page":"1477-1495.e15","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Hypoxia shapes both therapeutic response and resistance in metastatic clear cell renal cell carcinoma"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3277-0064","authenticated-orcid":false,"given":"Lynda","family":"Vuong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew E.","family":"Cornish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Pfeil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yash","family":"Khandwala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doris X.T.","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo A.","family":"Mascareno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Rittenhouse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip M.","family":"Rappold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef","family":"Leibold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erich A.","family":"Sabio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlene","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangliang","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mojca","family":"Adlesic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oguz","family":"Akin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Flynn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chirag","family":"Krishna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Lopez Sanmiguel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca A.","family":"Sager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiak J.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renzo G.","family":"Di Natale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle A.","family":"Blum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan A.","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian J.","family":"Frew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Chowell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Bei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"Solit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Ostrovnaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Motzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin H.","family":"Voss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritesh R.","family":"Kotecha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy A.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartland W.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengshen","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming O.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Ari","family":"Hakimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ccell.2026.05.007_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102718","article-title":"The more the merrier? Evidence and efficacy of immune checkpoint- and tyrosine kinase inhibitor combinations in advanced solid cancers","volume":"125","author":"Starzer","year":"2024","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.ccell.2026.05.007_bib2","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/s41571-024-00886-y","article-title":"Antiangiogenic-immune-checkpoint inhibitor combinations: lessons from phase III clinical trials","volume":"21","author":"Kuo","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ccell.2026.05.007_bib3","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.jtho.2023.12.023","article-title":"Pembrolizumab With or Without Lenvatinib for First-Line Metastatic NSCLC With Programmed Cell Death-Ligand 1 Tumor Proportion Score of at least 1% (LEAP-007): A Randomized, Double-Blind, Phase 3 Trial","volume":"19","author":"Yang","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ccell.2026.05.007_bib4","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/j.annonc.2025.08.008","article-title":"Randomized, double-blind, phase III LEAP-003 study of first-line lenvatinib plus pembrolizumab versus placebo plus pembrolizumab for unresectable or metastatic melanoma","volume":"36","author":"Arance","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ccell.2026.05.007_bib5","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.eururo.2022.06.016","article-title":"The 2022 World Health Organization Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours","volume":"82","author":"Moch","year":"2022","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ccell.2026.05.007_bib6","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1038\/s41591-020-1093-z","article-title":"Targeting the HIF2\u2013VEGF axis in renal cell carcinoma","volume":"26","author":"Choueiri","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2026.05.007_bib7","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.annonc.2024.07.727","article-title":"Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial","volume":"35","author":"Tannir","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ccell.2026.05.007_bib8","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1200\/JCO.23.01569","article-title":"Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study","volume":"42","author":"Motzer","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2026.05.007_bib9","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.eururo.2023.06.006","article-title":"Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study","volume":"84","author":"Plimack","year":"2023","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ccell.2026.05.007_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.102994","article-title":"Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial","volume":"9","author":"Powles","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.ccell.2026.05.007_bib11","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41591-018-0053-3","article-title":"Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma","volume":"24","author":"McDermott","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2026.05.007_bib12","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.ccell.2021.03.007","article-title":"Single-cell sequencing links multiregional immune landscapes and tissue-resident T cells in ccRCC to tumor topology and therapy efficacy","volume":"39","author":"Krishna","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccell.2026.05.007_bib13","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/j.ccell.2021.10.001","article-title":"Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma","volume":"39","author":"Au","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccell.2026.05.007_bib14","doi-asserted-by":"crossref","first-page":"e004316","DOI":"10.1136\/jitc-2021-004316","article-title":"Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma","volume":"10","author":"Motzer","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ccell.2026.05.007_bib15","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1038\/s41591-020-1044-8","article-title":"Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial","volume":"26","author":"Motzer","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2026.05.007_bib16","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s13073-022-01146-3","article-title":"Spatiotemporal evolution of the clear cell renal cell carcinoma microenvironment links intra-tumoral heterogeneity to immune escape","volume":"14","author":"Golkaram","year":"2022","journal-title":"Genome Med."},{"key":"10.1016\/j.ccell.2026.05.007_bib17","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1158\/2159-8290.CD-18-0957","article-title":"Transcriptomic Profiling of the Tumor Microenvironment Reveals Distinct Subgroups of Clear Cell Renal Cell Cancer: Data from a Randomized Phase III Trial","volume":"9","author":"Hakimi","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ccell.2026.05.007_bib18","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.ccell.2020.10.011","article-title":"Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade","volume":"38","author":"Motzer","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccell.2026.05.007_bib19","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1016\/j.immuni.2025.10.013","article-title":"Myeloid cells mediate interferon-driven resistance to immunotherapy in advanced renal cell carcinoma","volume":"58","author":"Bi","year":"2025","journal-title":"Immunity"},{"key":"10.1016\/j.ccell.2026.05.007_bib20","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41586-024-08076-7","article-title":"Differentiation fate of a stem-like CD4 T cell controls immunity to cancer","volume":"636","author":"Cardenas","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2026.05.007_bib21","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.ccell.2021.02.013","article-title":"Progressive immune dysfunction with advancing disease stage in renal cell carcinoma","volume":"39","author":"Braun","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccell.2026.05.007_bib22","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1016\/j.ccell.2022.11.001","article-title":"Mapping single-cell transcriptomes in the intra-tumoral and associated territories of kidney cancer","volume":"40","author":"Li","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccell.2026.05.007_bib23","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1016\/j.cell.2021.04.038","article-title":"Single-cell protein activity analysis identifies recurrence-associated renal tumor macrophages","volume":"184","author":"Obradovic","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.ccell.2026.05.007_bib24","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/s41588-024-01662-5","article-title":"Multi-omic profiling of clear cell renal cell carcinoma identifies metabolic reprogramming associated with disease progression","volume":"56","author":"Hu","year":"2024","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ccell.2026.05.007_bib25","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/s42003-020-01625-6","article-title":"Mapping the immune environment in clear cell renal carcinoma by single-cell genomics","volume":"4","author":"Borcherding","year":"2021","journal-title":"Commun. Biol."},{"key":"10.1016\/j.ccell.2026.05.007_bib26","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1016\/j.ccell.2025.07.010","article-title":"Comprehensive tumor-immune profiling reveals mediators of paradoxical immune sensitivity in sarcomatoid renal cell carcinoma","volume":"43","author":"Salgia","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccell.2026.05.007_bib27","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.ccell.2021.02.015","article-title":"Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma","volume":"39","author":"Bi","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccell.2026.05.007_bib28","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/nm.4343","article-title":"Combined mutation in Vhl, Trp53 and Rb1 causes clear cell renal cell carcinoma in mice","volume":"23","author":"Harlander","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2026.05.007_bib29","doi-asserted-by":"crossref","first-page":"4111","DOI":"10.1038\/s41467-020-17873-3","article-title":"HIF-1\u03b1 and HIF-2\u03b1 differently regulate tumour development and inflammation of clear cell renal cell carcinoma in mice","volume":"11","author":"Hoefflin","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ccell.2026.05.007_bib30","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/d41573-023-00186-7","article-title":"The renal cell carcinoma drug market","volume":"23","author":"Tur","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ccell.2026.05.007_bib31","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.ccell.2024.03.002","article-title":"Impact of renal cell carcinoma molecular subtypes on immunotherapy and targeted therapy outcomes","volume":"42","author":"Saliby","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccell.2026.05.007_bib32","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/s41568-024-00736-0","article-title":"Targeting the tumour vasculature: from vessel destruction to promotion","volume":"24","author":"Guelfi","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ccell.2026.05.007_bib33","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1126\/science.adi7657","article-title":"New partners reinvigorate a once-touted cancer treatment","volume":"380","author":"Leslie","year":"2023","journal-title":"Science"},{"key":"10.1016\/j.ccell.2026.05.007_bib34","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1126\/science.aaf4405","article-title":"Hypoxic control of metastasis","volume":"352","author":"Rankin","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.ccell.2026.05.007_bib35","doi-asserted-by":"crossref","first-page":"17561","DOI":"10.1073\/pnas.1215397109","article-title":"Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy","volume":"109","author":"Huang","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ccell.2026.05.007_bib36","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1038\/s41598-024-52268-0","article-title":"Therapy-induced modulation of tumor vasculature and oxygenation in a murine glioblastoma model quantified by deep learning-based feature extraction","volume":"14","author":"Bauer","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ccell.2026.05.007_bib37","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41586-020-2836-1","article-title":"TGF-\u03b2 suppresses type 2 immunity to cancer","volume":"587","author":"Liu","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2026.05.007_bib38","first-page":"928","article-title":"Glucose Transporter Glut-1 Expression Correlates with Tumor Hypoxia and Predicts Metastasis-free Survival in Advanced Carcinoma of the Cervix1","volume":"7","author":"Airley","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ccell.2026.05.007_bib39","doi-asserted-by":"crossref","first-page":"3993","DOI":"10.1111\/cas.13806","article-title":"Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model","volume":"109","author":"Kimura","year":"2018","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ccell.2026.05.007_bib40","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s00262-007-0441-x","article-title":"The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients","volume":"57","author":"Osada","year":"2008","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ccell.2026.05.007_bib41","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s12967-018-1578-4","article-title":"PBMC fixation and processing for Chromium single-cell RNA sequencing","volume":"16","author":"Chen","year":"2018","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.ccell.2026.05.007_bib42","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/s41591-020-0839-y","article-title":"Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma","volume":"26","author":"Braun","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2026.05.007_bib43","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1158\/2159-8290.CD-21-0925","article-title":"A Targetable Myeloid Inflammatory State Governs Disease Recurrence in Clear-Cell Renal Cell Carcinoma","volume":"12","author":"Rappold","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ccell.2026.05.007_bib44","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/s41587-021-01033-z","article-title":"Differential abundance testing on single-cell data using k-nearest neighbor graphs","volume":"40","author":"Dann","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ccell.2026.05.007_bib45","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1126\/science.ade2292","article-title":"CXCL9:SPP1 macrophage polarity identifies a network of cellular programs that control human cancers","volume":"381","author":"Bill","year":"2023","journal-title":"Science"},{"key":"10.1016\/j.ccell.2026.05.007_bib46","doi-asserted-by":"crossref","first-page":"CT171","DOI":"10.1158\/1538-7445.AM2020-CT171","article-title":"Abstract CT171: Phase I study of BLZ945 alone and with spartalizumab (PDR001) in patients (pts) with advanced solid tumors","volume":"80","author":"Lin","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.ccell.2026.05.007_bib47","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1016\/j.immuni.2023.10.010","article-title":"Reprogramming tumor-associated macrophages to outcompete endovascular endothelial progenitor cells and suppress tumor neoangiogenesis","volume":"56","author":"Do","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.ccell.2026.05.007_bib48","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/nature21724","article-title":"Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming","volume":"544","author":"Tian","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2026.05.007_bib49","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41586-020-2836-1","article-title":"TGF-beta suppresses type 2 immunity to cancer","volume":"587","author":"Liu","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2026.05.007_bib50","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.cell.2020.03.048","article-title":"Single-Cell Analyses Inform Mechanisms of Myeloid-Targeted Therapies in Colon Cancer","volume":"181","author":"Zhang","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.ccell.2026.05.007_bib51","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1038\/s41586-024-08290-3","article-title":"Evolution of myeloid-mediated immunotherapy resistance in prostate cancer","volume":"637","author":"Lyu","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2026.05.007_bib52","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/s41573-022-00520-5","article-title":"Macrophages as tools and targets in cancer therapy","volume":"21","author":"Mantovani","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ccell.2026.05.007_bib53","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1158\/1535-7163.MCT-05-0359","article-title":"Inhibition of phosphorylation of the colony-stimulating factor-1 receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitors","volume":"5","author":"Guo","year":"2006","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ccell.2026.05.007_bib54","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1016\/j.immuni.2022.10.002","article-title":"Tumor-associated macrophages expressing the transcription factor IRF8 promote T cell exhaustion in cancer","volume":"55","author":"Nixon","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.ccell.2026.05.007_bib55","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.coi.2017.03.006","article-title":"Plasma cell and memory B cell differentiation from the germinal center","volume":"45","author":"Suan","year":"2017","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.ccell.2026.05.007_bib56","doi-asserted-by":"crossref","DOI":"10.1002\/eji.202350373","article-title":"Optimal AID expression and efficient immunoglobulin class switch recombination are dependent on the hypoxia-inducible factor","volume":"53","author":"Heyer","year":"2023","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.ccell.2026.05.007_bib57","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/nri2322","article-title":"The regulation of IgA class switching","volume":"8","author":"Cerutti","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ccell.2026.05.007_bib58","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/nature24302","article-title":"Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity","volume":"551","author":"Shalapour","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2026.05.007_bib59","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/nature14395","article-title":"Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy","volume":"521","author":"Shalapour","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2026.05.007_bib60","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","article-title":"B cells and tertiary lymphoid structures promote immunotherapy response","volume":"577","author":"Helmink","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2026.05.007_bib61","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1038\/s43018-021-00232-6","article-title":"Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression","volume":"2","author":"Vanhersecke","year":"2021","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.ccell.2026.05.007_bib62","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.immuni.2022.02.001","article-title":"Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer","volume":"55","author":"Meylan","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.ccell.2026.05.007_bib63","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/s43018-024-00896-w","article-title":"Immunogenomic determinants of exceptional response to immune checkpoint inhibition in renal cell carcinoma","volume":"6","author":"Jammihal","year":"2025","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.ccell.2026.05.007_bib64","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1158\/2159-8290.CD-24-0991","article-title":"Presence of tertiary lymphoid structures and exhausted tissue-resident T cells determines clinical response to PD-1 blockade in renal cell carcinoma","volume":"15","author":"Hugaboom","year":"2025","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ccell.2026.05.007_bib65","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/s41587-019-0068-4","article-title":"Characterization of cell fate probabilities in single-cell data with Palantir","volume":"37","author":"Setty","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ccell.2026.05.007_bib66","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.ccell.2023.02.017","article-title":"B cells in the tumor microenvironment: Multi-faceted organizers, regulators, and effectors of anti-tumor immunity","volume":"41","author":"Laumont","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccell.2026.05.007_bib67","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1038\/s41559-021-01456-6","article-title":"Selection of metastasis competent subclones in the tumour interior","volume":"5","author":"Zhao","year":"2021","journal-title":"Nat. Ecol. Evol."},{"key":"10.1016\/j.ccell.2026.05.007_bib68","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-59529-0","article-title":"SPP1 + macrophages cause exhaustion of tumor-specific T cells in liver metastases","volume":"16","author":"Trehan","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ccell.2026.05.007_bib69","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1038\/s41588-025-02380-2","article-title":"TGF-\u03b2 builds a dual immune barrier in colorectal cancer by impairing T cell recruitment and instructing immunosuppressive SPP1+ macrophages","volume":"57","author":"Henriques","year":"2025","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ccell.2026.05.007_bib70","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.ccell.2025.03.036","article-title":"Bone metastases diminish extraosseous response to checkpoint blockade immunotherapy through osteopontin-producing osteoclasts","volume":"43","author":"Cheng","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccell.2026.05.007_bib71","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1158\/2326-6066.CIR-24-1146","article-title":"SPP1+ Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8+ T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma","volume":"13","author":"Jiang","year":"2025","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ccell.2026.05.007_bib72","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/s41591-024-03398-5","article-title":"Prediction of checkpoint inhibitor immunotherapy efficacy for cancer using routine blood tests and clinical data","volume":"31","author":"Yoo","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2026.05.007_bib73","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ccell.2026.05.007_bib74","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1016\/S0140-6736(19)30723-8","article-title":"Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial","volume":"393","author":"Rini","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ccell.2026.05.007_bib75","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.annonc.2024.12.003","article-title":"Biomarker analyses from the phase III randomized CLEAR trial: lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma","volume":"36","author":"Motzer","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ccell.2026.05.007_bib76","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1200\/JCO.2025.43.5_suppl.572","article-title":"Vasculo-immune modulatory effects of anti-VEGF therapy in metastatic clear cell renal cell carcinoma: The A-PREDICT trial","volume":"43","author":"Au","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2026.05.007_bib77","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1158\/2159-8290.CD-23-1300","article-title":"Spatially Segregated Macrophage Populations Predict Distinct Outcomes in Colon Cancer","volume":"14","author":"Matusiak","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ccell.2026.05.007_bib78","series-title":"Cabozantinib (C) in Combination with Nivolumab (N) and Ipilimumab (I) in Previously Untreated Advanced Renal Cell Carcinoma (aRCC): Final Results of COSMIC-313","author":"Albiges","year":"2025"},{"key":"10.1016\/j.ccell.2026.05.007_bib79","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s43018-025-00922-5","article-title":"Neoadjuvant cabozantinib for locally advanced nonmetastatic clear cell renal cell carcinoma: a phase 2 trial","volume":"6","author":"Bilen","year":"2025","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.ccell.2026.05.007_bib80","doi-asserted-by":"crossref","first-page":"e004059","DOI":"10.1136\/jitc-2021-004059","article-title":"In silico modeling of combination systemic therapy for advanced renal cell carcinoma","volume":"9","author":"Kotecha","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ccell.2026.05.007_bib81","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.immuni.2025.02.017","article-title":"Anti-vascular endothelial growth factor treatment potentiates immune checkpoint blockade through a BAFF- and IL-12-dependent reprogramming of the TME","volume":"58","author":"Benmebarek","year":"2025","journal-title":"Immunity"},{"key":"10.1016\/j.ccell.2026.05.007_bib82","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.euo.2019.10.002","article-title":"The Association Between Small Primary Tumor Size and Prognosis in Metastatic Renal Cell Carcinoma: Insights from Two Independent Cohorts of Patients Who Underwent Cytoreductive Nephrectomy","volume":"3","author":"DiNatale","year":"2020","journal-title":"Eur. Urol. Oncol."},{"key":"10.1016\/j.ccell.2026.05.007_bib83","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ccr.2009.01.021","article-title":"Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis","volume":"15","author":"Ebos","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccell.2026.05.007_bib84","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ccr.2009.01.027","article-title":"Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis","volume":"15","author":"P\u00e0ez-Ribes","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccell.2026.05.007_bib85","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1038\/bjc.2011.81","article-title":"Chronic exposure of colorectal cancer cells to bevacizumab promotes compensatory pathways that mediate tumour cell migration","volume":"104","author":"Fan","year":"2011","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ccell.2026.05.007_bib86","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.eururo.2014.10.034","article-title":"Evidence and Clinical Relevance of Tumor Flare in Patients Who Discontinue Tyrosine Kinase Inhibitors for Treatment of Metastatic Renal Cell Carcinoma","volume":"68","author":"Iacovelli","year":"2015","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ccell.2026.05.007_bib87","doi-asserted-by":"crossref","first-page":"ix77","DOI":"10.1093\/annonc\/mdx697.011","article-title":"Disease flare phenomenon after multi-tyrosine kinase inhibitor discontinuation: a retrospective analysis","volume":"28","author":"Shimokawa","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ccell.2026.05.007_bib88","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/S1470-2045(21)00241-2","article-title":"Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111\/KEYNOTE-146): a phase 1b\/2 study","volume":"22","author":"Lee","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ccell.2026.05.007_bib89","author":"Hothorn"},{"key":"10.1016\/j.ccell.2026.05.007_bib90","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms14049","article-title":"Massively parallel digital transcriptional profiling of single cells","volume":"8","author":"Zheng","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ccell.2026.05.007_bib91","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1016\/j.cell.2019.05.031","article-title":"Comprehensive Integration of Single-Cell Data","volume":"177","author":"Stuart","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.ccell.2026.05.007_bib92","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cels.2018.11.005","article-title":"Scrublet: Computational Identification of Cell Doublets in Single-Cell Transcriptomic Data","volume":"8","author":"Wolock","year":"2019","journal-title":"Cell Syst."},{"key":"10.1016\/j.ccell.2026.05.007_bib93","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/s41590-018-0276-y","article-title":"Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage","volume":"20","author":"Aran","year":"2019","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ccell.2026.05.007_bib94","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1038\/s41592-019-0619-0","article-title":"Fast, sensitive and accurate integration of single-cell data with Harmony","volume":"16","author":"Korsunsky","year":"2019","journal-title":"Nat. Methods"},{"key":"10.1016\/j.ccell.2026.05.007_bib95","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1038\/s41556-024-01469-w","article-title":"LIANA+ provides an all-in-one framework for cell\u2013cell communication inference","volume":"26","author":"Dimitrov","year":"2024","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.ccell.2026.05.007_bib96","article-title":"Combining LIANA and Tensor-cell2cell to decipher cell-cell communication across multiple samples","volume":"4","author":"Baghdassarian","year":"2024","journal-title":"Cell Rep. Methods"},{"key":"10.1016\/j.ccell.2026.05.007_bib97","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/s41592-021-01358-2","article-title":"Squidpy: a scalable framework for spatial omics analysis","volume":"19","author":"Palla","year":"2022","journal-title":"Nat. Methods"},{"key":"10.1016\/j.ccell.2026.05.007_bib98","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/s43018-022-00356-3","article-title":"Cell type and gene expression deconvolution with BayesPrism enables Bayesian integrative analysis across bulk and single-cell RNA sequencing in oncology","volume":"3","author":"Chu","year":"2022","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.ccell.2026.05.007_bib111","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1003118","article-title":"Software for computing and annotating genomic ranges","volume":"9","author":"Lawrence","year":"2013","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.ccell.2026.05.007_bib113","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol."},{"key":"10.1016\/j.ccell.2026.05.007_bib115","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1471-2105-14-7","article-title":"GSVA: gene set variation analysis for microarray and RNA-seq data","volume":"14","author":"H\u00e4nzelmann","year":"2013","journal-title":"BMC Bioinf."},{"key":"10.1016\/j.ccell.2026.05.007_bib118","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1038\/ncomms3612","article-title":"Inferring tumour purity and stromal and immune cell admixture from expression data","volume":"4","author":"Yoshihara","year":"2013","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ccell.2026.05.007_bib99","author":"Wei"},{"key":"10.1016\/j.ccell.2026.05.007_bib100","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ccell.2026.05.007_bib101","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1093\/bioinformatics\/bts356","article-title":"RSeQC: quality control of RNA-seq experiments","volume":"28","author":"Wang","year":"2012","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ccell.2026.05.007_bib102","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1038\/s41596-023-00881-0","article-title":"An end-to-end workflow for multiplexed image processing and analysis","volume":"18","author":"Windhager","year":"2023","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.ccell.2026.05.007_bib103","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.cels.2018.02.010","article-title":"Compensation of Signal Spillover in Suspension and Imaging Mass Cytometry","volume":"6","author":"Chevrier","year":"2018","journal-title":"Cell Syst."},{"key":"10.1016\/j.ccell.2026.05.007_bib104","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.cell.2015.05.047","article-title":"Data-Driven Phenotypic Dissection of AML Reveals Progenitor-like Cells that Correlate with Prognosis","volume":"162","author":"Levine","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.ccell.2026.05.007_bib105","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.cels.2021.08.012","article-title":"Automated assignment of cell identity from single-cell multiplexed imaging and proteomic data","volume":"12","author":"Geuenich","year":"2021","journal-title":"Cell Syst."},{"key":"10.1016\/j.ccell.2026.05.007_bib106","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/s41587-021-01094-0","article-title":"Whole-cell segmentation of tissue images with human-level performance using large-scale data annotation and deep learning","volume":"40","author":"Greenwald","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ccell.2026.05.007_bib107","article-title":"Rakaia: interactive discovery of spatial biology at scale","author":"Watson","year":"2025","journal-title":"bioRxiv"},{"key":"10.1016\/j.ccell.2026.05.007_bib108","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s12915-022-01376-2","article-title":"Griottes: a generalist tool for network generation from segmented tissue images","volume":"20","author":"Ronteix","year":"2022","journal-title":"BMC Biol."},{"key":"10.1016\/j.ccell.2026.05.007_bib109","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/nature12222","article-title":"Comprehensive molecular characterization of clear cell renal cell carcinoma","volume":"499","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2026.05.007_bib110","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.eururo.2020.12.029","article-title":"Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial","volume":"79","author":"Motzer","year":"2021","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ccell.2026.05.007_bib112","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1080\/15592294.2015.1115175","article-title":"Identification of a new locus and validation of previously reported loci showing differential methylation associated with smoking. The REGICOR study","volume":"10","author":"Sayols-Baixeras","year":"2015","journal-title":"Epigenetics"},{"key":"10.1016\/j.ccell.2026.05.007_bib114","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/ng1180","article-title":"PGC-1\u03b1-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes","volume":"34","author":"Mootha","year":"2003","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ccell.2026.05.007_bib116","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.immuni.2013.10.003","article-title":"Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer","volume":"39","author":"Bindea","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.ccell.2026.05.007_bib117","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1186\/s13059-016-1092-z","article-title":"Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures","volume":"17","author":"\u015eenbabao\u011flu","year":"2016","journal-title":"Genome Biol."},{"key":"10.1016\/j.ccell.2026.05.007_bib119","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ccr.2013.06.004","article-title":"A core human primary tumor angiogenesis signature identifies the endothelial orphan receptor ELTD1 as a key regulator of angiogenesis","volume":"24","author":"Masiero","year":"2013","journal-title":"Cancer Cell"}],"container-title":["Cancer Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535610826002527?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535610826002527?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T20:50:30Z","timestamp":1786481430000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1535610826002527"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":119,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1535610826002527"],"URL":"https:\/\/doi.org\/10.1016\/j.ccell.2026.05.007","relation":{},"ISSN":["1535-6108"],"issn-type":[{"value":"1535-6108","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hypoxia shapes both therapeutic response and resistance in metastatic clear cell renal cell carcinoma","name":"articletitle","label":"Article Title"},{"value":"Cancer Cell","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccell.2026.05.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}